Nebulized Lidocaine vs 3% Sodium Chloride in Pediatric Adenoid/Tonsil Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-16
SponsorSakarya University

About this trial

This prospective, randomized clinical trial aims to evaluate the effect of preoperative nebulized lidocaine and nebulized 3% hypertonic sodium chloride (NaCl) on the incidence of postoperative respiratory complications in pediatric patients undergoing adenoidectomy and/or adenotonsillectomy. Lidocaine, a versatile sodium channel blocker, has shown antitussive, bronchodilatory, and anti-inflammatory benefits when nebulized, and has been safely used in children for respiratory procedures. Hypertonic 3% NaCl is known to improve mucociliary clearance, reduce airway edema, and enhance secretion mobilization, particularly in pediatric respiratory conditions. Both agents have demonstrated individual safety and efficacy in respiratory management, yet their preoperative nebulized use for preventing postoperative respiratory adverse events (PRAEs) in pediatric airway surgery has not been previously studied. This trial seeks to determine whether preoperative nebulization with these agents can reduce postoperative respiratory complications, improve recovery, and enhance perioperative safety in this high-risk population.

Eligibility criteria

Qualifiers

Patients who agree to participate in the study

Patients undergoing adenoidectomy or adenotonsillectomy

Patients with ASA physical status 1-2

Children aged 18 months to 16 years

Disqualifiers

Patients who do not agree to participate in the study

Patients with allergy to lidocaine or 3% NaCl

Patients with ASA physical status 3-4

Patients whose surgery duration exceeds 1 hour

Trial design

Treatments tested in this trial

  • Nebulize Lidocaine
  • Nebulize %3 Sodium Chloride

Treatment groups

90 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators